Brii Biosciences Limited (BRII-B) disclosed a share repurchase of 359,000 ordinary shares on 6 November 2026, conducted on the Hong Kong Stock Exchange under its existing buy-back mandate approved on 16 June 2026.
The shares were acquired at prices ranging between HK$1.015 and HK$1.05, with a volume-weighted average consideration of HK$1.035 per share. Total cash outlay for the transaction amounted to HK$0.37 million.
Key post-transaction metrics: • Outstanding shares (excluding treasury shares) decreased by 0.05 % to 720.22 million. • Treasury share balance rose to 15.62 million from 15.26 million. • Total issued shares remained unchanged at 735.84 million, as all repurchased shares were retained as treasury stock. • Cumulative buybacks under the June mandate have reached 2.90 million shares, representing 0.40 % of the share count on the mandate date. • The company is restricted from issuing new shares or disposing of treasury shares until 6 December 2026, in line with Hong Kong Listing Rules.
The filing confirms that the repurchase complied with Main Board Rule 10.06 and that no material changes have occurred to the previously issued Explanatory Statement dated 24 April 2026.
Comments